Update of the drug resistance mutations in HIV-1: March 2013.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

133 citing papers in PubMed.

1. Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.PloS one · 2023
   Trial
2. The transmission of drug-resistant strains of HIV in heterosexual populations based on genetic sequences.PloS one · 2021
   Trial
3. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.AIDS (London, England) · 2017
   Trial
4. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.Journal of the International AIDS Society · 2017
   Trial
5. Once vs twice-daily abacavir and lamivudine in African children.AIDS (London, England) · 2016
   Trial
6. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Journal of acquired immune deficiency syndromes (1999) · 2016
   Trial
7. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.HIV medicine · 2016
   Trial
8. Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.PloS one · 2016
   Trial
9. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.The Pediatric infectious disease journal · 2015
   Trial
10. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.PloS one · 2015
    Trial
11. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.PloS one · 2015
    Trial
12. Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.The Journal of antimicrobial chemotherapy · 2014
    Trial
13. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial
14. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.PloS one · 2014
    Trial
15. Exploring evolutionary trajectories of drug resistance.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
16. Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
17. Immunomodulatory biomaterials in HIV-1 infection prevention, control and treatment.Frontiers in immunology · 2025
    Review
18. A survey of resistance mutations to reverse transcriptase inhibitors (RTIs) among HIV-1 patients in northeast of Iran.Molecular biology research communications · 2024
    Article
19. Evidence for Recombination as an Evolutionary Mechanism in Coronaviruses: Is SARS-CoV-2 an Exception?Frontiers in public health · 2022
    Article
20. Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population.Virusdisease · 2021
    Article

73 more citing papers are in PubMed but not listed here.

Corrections and comments

• Erratum issued

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as